Bright Minds Valuation
| DRUG Stock | USD 39.18 1.07 2.81% |
At this time, the firm appears to be overvalued. Bright Minds Biosciences shows a prevailing Real Value of $16.42 per share. The current price of the firm is $39.18. Our model approximates the value of Bright Minds Biosciences from analyzing the firm fundamentals such as Current Valuation of 274.15 M, return on equity of -0.52, and Shares Owned By Insiders of 27.28 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Bright Minds' valuation include:
Price Book 61.447 | Enterprise Value 274.2 M | Enterprise Value Ebitda (0.07) |
Overvalued
Today
Please note that Bright Minds' price fluctuation is out of control at this time. Calculation of the real value of Bright Minds Biosciences is based on 3 months time horizon. Increasing Bright Minds' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Bright stock is determined by what a typical buyer is willing to pay for full or partial control of Bright Minds Biosciences. Since Bright Minds is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bright Stock. However, Bright Minds' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 39.18 | Real 16.42 | Target 4.87 | Hype 37.18 | Naive 47.06 |
The real value of Bright Stock, also known as its intrinsic value, is the underlying worth of Bright Minds Biosciences Company, which is reflected in its stock price. It is based on Bright Minds' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Bright Minds' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Bright Minds Biosciences helps investors to forecast how Bright stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bright Minds more accurately as focusing exclusively on Bright Minds' fundamentals will not take into account other important factors: When choosing an evaluation method for Bright Minds Biosciences, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Bright Minds Cash |
|
Bright Valuation Trend
Comparing Bright Minds' enterprise value against its market capitalization is a good way to estimate the value of Bright Minds Biosciences uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Bright Minds Total Value Analysis
Bright Minds Biosciences is currently anticipated to have valuation of 274.15 M with market capitalization of 278.53 M, debt of 73.55 K, and cash on hands of 8.64 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Bright Minds fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
274.15 M | 278.53 M | 73.55 K | 8.64 M |
Bright Minds Asset Utilization
One of the ways to look at asset utilization of Bright is to check how much profit was generated for every dollar of assets it reports. Bright Minds Biosciences shows a negative utilization of assets of -0.29 percent, losing $0.002886 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Bright Minds Biosciences shows how discouraging it operates for each dollar spent on its assets.Bright Minds Ownership Allocation
The market capitalization of Bright Minds Biosciences is $278.53 Million. Bright Minds Biosciences retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Bright Minds Profitability Analysis
Net Loss for the year was (7.37 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Bright Minds' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Bright Minds and how it compares across the competition.
About Bright Minds Valuation
The stock valuation mechanism determines Bright Minds' current worth on a weekly basis. Our valuation model uses a comparative analysis of Bright Minds. We calculate exposure to Bright Minds's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Bright Minds's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -65.2 K | -61.9 K |
Bright Minds Growth Indicators
Investing in growth stocks can be very risky. If the company such as Bright Minds does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 3.7 M |
Bright Minds Current Valuation Indicators
Valuation refers to the process of determining the present value of Bright Minds Biosciences and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Bright we look at many different elements of the entity such as Bright's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Bright Minds, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Bright Minds' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Bright Minds' worth.Complementary Tools for Bright Stock analysis
When running Bright Minds' price analysis, check to measure Bright Minds' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bright Minds is operating at the current time. Most of Bright Minds' value examination focuses on studying past and present price action to predict the probability of Bright Minds' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bright Minds' price. Additionally, you may evaluate how the addition of Bright Minds to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |